The news that Novartis AG has terminated a late-stage peanut allergy trial of one of its more closely watched assets, ligelizumab, looks like good news for other players in the space, notably DBV Technologies and ALK-Abello A/S.
It emerged last week that the Swiss major had halted a Phase III trial of ligelizumab for peanut allergy based...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?